The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enable...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-10-01
|
Series: | Genomics, Proteomics & Bioinformatics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1672022916301413 |
id |
doaj-19fa756467a2427c9ba3208fcfa8d331 |
---|---|
record_format |
Article |
spelling |
doaj-19fa756467a2427c9ba3208fcfa8d3312020-11-25T01:06:25ZengElsevierGenomics, Proteomics & Bioinformatics1672-02292016-10-0114529831310.1016/j.gpb.2016.03.008Shabbir Ahmed0Zhan Zhou1Jie Zhou2Shu-Qing Chen3Department of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaDepartment of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaDepartment of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaDepartment of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaThe interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.http://www.sciencedirect.com/science/article/pii/S1672022916301413PharmacogenomicsPrecision medicineGenetic polymorphismPhase-I drug-metabolizing enzymesDrug transporters |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shabbir Ahmed Zhan Zhou Jie Zhou Shu-Qing Chen |
spellingShingle |
Shabbir Ahmed Zhan Zhou Jie Zhou Shu-Qing Chen Genomics, Proteomics & Bioinformatics Pharmacogenomics Precision medicine Genetic polymorphism Phase-I drug-metabolizing enzymes Drug transporters |
author_facet |
Shabbir Ahmed Zhan Zhou Jie Zhou Shu-Qing Chen |
author_sort |
Shabbir Ahmed |
publisher |
Elsevier |
series |
Genomics, Proteomics & Bioinformatics |
issn |
1672-0229 |
publishDate |
2016-10-01 |
description |
The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient. |
topic |
Pharmacogenomics Precision medicine Genetic polymorphism Phase-I drug-metabolizing enzymes Drug transporters |
url |
http://www.sciencedirect.com/science/article/pii/S1672022916301413 |
_version_ |
1725190333348708352 |